{"id":1064,"date":"2021-05-28T06:35:40","date_gmt":"2021-05-28T06:35:40","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=1064"},"modified":"2021-05-28T06:35:40","modified_gmt":"2021-05-28T06:35:40","slug":"25-may-2021-plitidepsin-discharge-rates-by-days-8-and-15-were-56-8-and-81-8","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/25-may-2021-plitidepsin-discharge-rates-by-days-8-and-15-were-56-8-and-81-8\/","title":{"rendered":"(25 May 2021) Plitidepsin- discharge rates by Days 8 and 15 were 56.8% and 81.8%"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p id=\"page-title\" class=\"highwire-cite-title\">Plitidepsin has a positive therapeutic index in adult patients with COVID-19 requiring hospitalization<\/p>\n<p class=\"\">https:\/\/www.medrxiv.org\/content\/10.1101\/2021.05.25.21257505v1<\/p>\n<p class=\"\">EudraCT #2020-001993-31 NCT #04382066- Plitidepsin is a marine-derived cyclic-peptide that inhibits SARS-CoV-2 replication at low nanomolar concentrations by the targeting of host protein eEF1A (eukaryotic translation-elongation-factor-1A). We evaluated a model of intervention with plitidepsin in hospitalized COVID-19 adult patients where three doses were assessed (1.5, 2 and 2.5 mg\/day for 3 days, as a 90-minute intravenous infusion) in 45 patients (15 per dose-cohort). Treatment was well tolerated, with only two Grade 3 treatment-related adverse events observed (hypersensitivity and diarrhea). The discharge rates by Days 8 and 15 were 56.8% and 81.8%, respectively, with data sustaining dose-effect. A mean 4.2 log10 viral load reduction was attained by Day 15. Improvement in inflammation markers was also noted in a seemingly dose-dependent manner. These results suggest that plitidepsin impacts the outcome of patients with COVID-19.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Plitidepsin has a positive therapeutic index in adult patients with COVID-19 requiring hospitalization https:\/\/www.medrxiv.org\/content\/10.1101\/2021.05.25.21257505v1 EudraCT #2020-001993-31 NCT #04382066- Plitidepsin is a marine-derived cyclic-peptide that inhibits SARS-CoV-2 replication at low nanomolar concentrations by the targeting of host protein eEF1A (eukaryotic translation-elongation-factor-1A).&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/25-may-2021-plitidepsin-discharge-rates-by-days-8-and-15-were-56-8-and-81-8\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(25 May 2021) Plitidepsin- discharge rates by Days 8 and 15 were 56.8% and 81.8%&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[6,141],"tags":[142],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/1064"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=1064"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/1064\/revisions"}],"predecessor-version":[{"id":1065,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/1064\/revisions\/1065"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=1064"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=1064"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=1064"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}